Kura Oncology Financial Statements
NASDAQ: KURAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kura Oncology revenue and earnings
In fiscal 2025, Kura Oncology generated $67.5 million in revenue, up 25.2% from fiscal 2024, its 2nd consecutive year of revenue growth. Kura Oncology reported a net loss of $278.7 million, compared with a loss of $174.0 million a year earlier. Operating margin was -449.9%.
Diluted earnings per share came in at -$3.18.
Summary generated from market data by MetaCap's automated system. Methodology
Kura Oncology income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67.48M | 53.88M | 0 | — | — | — | — | — | — | — |
| Revenue growth (YoY) | +25.24% | — | — | — | — | — | — | — | — | — |
| Operating Expenses | 371.11M | 247.08M | 165.80M | 139.87M | 131.26M | 91.90M | 67.48M | 62.88M | 36.08M | 28.37M |
| Research & Development | 251.07M | 169.97M | 115.23M | 92.81M | 84.72M | 60.40M | 47.83M | 46.79M | 26.43M | — |
| Selling, General & Admin | 119.98M | 77.11M | 50.57M | — | — | — | — | — | — | — |
| Operating Income | -303.63M | -193.19M | -165.80M | -139.87M | — | — | — | — | — | — |
| Interest Expense | 1.51M | 1.62M | 1.55M | 229.00K | 414.00K | 578.00K | 580.00K | 970.00K | 888.00K | 577.00K |
| Other Income (Expense) | 25.26M | 21.23M | 13.17M | 4.03M | 792.00K | 2.27M | 4.34M | 2.44M | 643.00K | 807.00K |
| Pretax Income | -278.37M | -171.97M | -152.63M | -135.84M | — | — | — | — | — | — |
| Income Tax | 297.00K | 2.02M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -278.67M | -173.98M | -152.63M | -135.84M | -130.47M | -89.63M | -63.14M | -60.45M | -35.43M | -27.56M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 | -1.69 | -1.51 | -1.72 | -1.52 | -1.47 |
| EPS (Diluted) | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 | -1.69 | -1.51 | -1.72 | -1.52 | -1.47 |
| Shares Outstanding (Basic) | 87.68M | 86.16M | 73.23M | 66.99M | 66.35M | 53.08M | 41.95M | 35.19M | 23.24M | 18.70M |
| Shares Outstanding (Diluted) | 87.68M | 86.16M | 73.23M | 66.99M | 66.35M | 53.08M | 41.95M | 35.19M | 23.24M | 18.70M |
| EBITDA | -302.60M | -192.35M | -164.96M | -139.11M | — | — | — | — | — | — |
| Operating Margin | -449.94% | -358.55% | — | — | — | — | — | — | — | — |
| Net Margin | -412.95% | -322.89% | — | — | — | — | — | — | — | — |
This table shows 10 annual periods of Kura Oncology's income statement, from FY 2025 back to FY 2016, across 17 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow KURA's reporting calendar. What is a income statement?